Management of obesity cardiomyopathy.
Therapy of acute exacerbations of congestive heart failure associated with obesity cardiomyopathy consists of dietary salt restriction, inspired oxygen, diuretics, and angiotensin-converting enzyme inhibitors or, if left ventricular systolic dysfunction is present, hydralazine/isosorbide dinitrate. Digitalis may be indicated in selected cases. These measures may also be useful chronically in association with weight loss. Substantial weight loss is capable of reversing all of the hemodynamic abnormalities associated with obesity except elevation of left ventricular filling pressure. Substantial weight loss may also reduce left ventricular mass and improve left ventricular diastolic filling in those with left ventricular hypertrophy before weight loss. Left ventricular systolic function also improves after weight loss in those with impaired pre-weight-loss systolic function. These beneficial effects of weight loss occur partly because of favorable alterations in left ventricular loading conditions. Substantial weight loss in patients with congestive heart failure associated with obesity cardiomyopathy produces a reversal of many of the clinical manifestations of cardiac decompensation and improves New York Heart Association functional class in most patients.
Alpert
M A
MA
Division of Cardiology, University of South Alabama, College of Medicine, Mobile 36617, USA.
D009202:Cardiomyopathies / Q000209:etiology / Q000628:therapy*; D003971:Diastole; D006321:Heart / Q000033:anatomy & histology; D006333:Heart Failure / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009765:Obesity / Q000150:complications*; D013599:Systole; D016277:Ventricular Function, Left; D016278:Ventricular Function, Right; D015431:Weight Loss